Lab Publishes New Paper on Preventing Multiple Myeloma

Graphic AbstractWe are pleased to announce the publication of our most recent paper titled “Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma,” which is free to view here.

Screening and prevention strategies have been used successfully in some solid tumor cancers, including breast, colon, and prostate. Multiple Myeloma is essentially always preceded by a non-malignant precursor stage called Monoclonal Gammopathy of Undetermined Significance (MGUS).  We believe that if we could identify ways to prevent the transition from pre-malignant MGUS to myeloma, we could reduce the personal, societal and economic burden of this devastating blood cancer.  In our paper, we review some possible prevention strategies. We also provide the first data on the incidence of sleep-disordered breathing and daytime sleepiness in myeloma patients, and comprehensively detail the multi-million dollar cost of treating this disease.

Thank you to all the lab members and collaborators who contributed to this effort. We hope this paper will be helpful to the scientific and patient community, and to find others who also believe that prevention is the best treatment.